ISB 2001 not checked

Ichnos Sciences SA

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
BCMA · CD38 · CD3
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants receive injection of ISB 2001 as determined in Part 1.”In the company’s words, NCT05862012 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Multiple Myeloma
Main trialPhase 1
“This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).”In the company’s words, NCT05862012 on ClinicalTrials.gov

Other drugs for Relapsed/Refractory Multiple Myeloma

All 133 drugs for Relapsed/Refractory Multiple Myeloma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Jul 2027 Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ISB 2001

Following is part of Solo: you see every change to ISB 2001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in